AR066970A1 - Derivado de 17 beta-ciano-18a-homo-19-nor-androst-4- eno, su uso y medicamento que lo contiene - Google Patents
Derivado de 17 beta-ciano-18a-homo-19-nor-androst-4- eno, su uso y medicamento que lo contieneInfo
- Publication number
- AR066970A1 AR066970A1 ARP080102498A ARP080102498A AR066970A1 AR 066970 A1 AR066970 A1 AR 066970A1 AR P080102498 A ARP080102498 A AR P080102498A AR P080102498 A ARP080102498 A AR P080102498A AR 066970 A1 AR066970 A1 AR 066970A1
- Authority
- AR
- Argentina
- Prior art keywords
- hydrogen
- group
- forming
- double bond
- androst
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
- C07J53/002—Carbocyclic rings fused
- C07J53/004—3 membered carbocyclic rings
- C07J53/007—3 membered carbocyclic rings in position 6-7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
- C07J53/002—Carbocyclic rings fused
- C07J53/004—3 membered carbocyclic rings
- C07J53/008—3 membered carbocyclic rings in position 15/16
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Toxicology (AREA)
- Pregnancy & Childbirth (AREA)
- Epidemiology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Derivados de 17beta-ciano-18a-homo-19-nor-androst-4-eno que poseen efectividad gestágena. Tienen la formula química general 1, en la cual Z se selecciona del grupo que comprende O, dos átomos de hidrogeno, NOR y NNHSO2R, donde R es hidrogeno o alquilo C1-4, R4 es hidrogeno o halogeno además o bien R6a, R6b juntos forman metileno o 1,2-etanodiilo o R6a es hidrogeno y R6b se selecciona del grupo que comprende hidrogeno, metilo y hidroximetileno, y R7 se selecciona del grupo que comprende hidrogeno, alquilo C1-4, alquenilo C2-3 y ciclopropilo o R6a es hidrogeno y R6b y R7 juntos forman metileno o se omiten por formacion de un enlace doble entre C6 y C7; R9, R10 son hidrogeno o se omiten por formacion de un enlace doble entre C9 y C10, R15, R16 son hidrogeno o juntos forman metileno, R17 se selecciona del grupo que comprende hidrogeno, alquilo C1-4 y alilo, donde al menos uno de los sustituyentes R4, R6a, R6b, R7, R15, R16 y R17 no es hidrogeno o R6b y R7 se omiten por formacion de un enlace doble entre C6 y C7 o se omiten por formacion de un enlace doble entre C1 y C2, y comprenden también sus solvatos, hidratos, estereoisomeros, diastereomeros, enantiomeros y sales. Estos compuestos se utilizan en medicamentos para el tratamiento de trastornos pre-, peri- y post-menopausia y también como gestágeno y antimineralocorticoide.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102007027636A DE102007027636A1 (de) | 2007-06-12 | 2007-06-12 | 17ß-Cyano-18a-homo-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel |
Publications (1)
Publication Number | Publication Date |
---|---|
AR066970A1 true AR066970A1 (es) | 2009-09-23 |
Family
ID=38858372
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080102498A AR066970A1 (es) | 2007-06-12 | 2008-06-12 | Derivado de 17 beta-ciano-18a-homo-19-nor-androst-4- eno, su uso y medicamento que lo contiene |
Country Status (21)
Country | Link |
---|---|
US (1) | US20090048218A1 (es) |
EP (1) | EP2178899B1 (es) |
JP (1) | JP2010529152A (es) |
KR (1) | KR20100017780A (es) |
CN (1) | CN101679477A (es) |
AR (1) | AR066970A1 (es) |
AU (1) | AU2008261277A1 (es) |
BR (1) | BRPI0813455A2 (es) |
CA (1) | CA2689563A1 (es) |
CL (1) | CL2008001721A1 (es) |
DE (1) | DE102007027636A1 (es) |
ES (1) | ES2397879T3 (es) |
IL (1) | IL202300A0 (es) |
MX (1) | MX2009013626A (es) |
PA (1) | PA8784201A1 (es) |
PE (1) | PE20090312A1 (es) |
RU (1) | RU2010100334A (es) |
TW (1) | TW200906846A (es) |
UY (1) | UY31145A1 (es) |
WO (1) | WO2008151745A1 (es) |
ZA (1) | ZA201000185B (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010066354A1 (de) * | 2008-12-12 | 2010-06-17 | Bayer Schering Pharma Aktiengesellschaft | VERWENDUNG VON 17β-CYANO-18A-HOMO-19-NOR-ANDROST-4-EN-DERIVATEN ZUR HERSTELLUNG EINES ARZNEIMITTELS IN DEPOT-FORM ZUR PARENTERALEN ANWENDUNG SOWIE DEPOT-ARZNEIMITTEL ENTHALTEND 17β-CYANO-18A-HOMO-19-NOR-ANDROST-4-EN-DERIVATE ZUR PARENTERALEN ANWENDUNG |
WO2012059594A1 (en) | 2010-11-04 | 2012-05-10 | Bayer Pharma Aktiengesellschaft | Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity |
US9388210B2 (en) | 2011-02-25 | 2016-07-12 | Washington University | Neuroactive 17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
CN113234114A (zh) | 2011-10-14 | 2021-08-10 | 萨奇治疗股份有限公司 | 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途 |
RS57390B1 (sr) | 2012-12-18 | 2018-09-28 | Univ Washington | Neuroaktivni 19-alkoksi-17-supstituisani steroidi, primenjivi u postupcima lečenja |
US9512170B2 (en) | 2013-03-01 | 2016-12-06 | Washington University | Neuroactive 13, 17-substituted steroids as modulators for GABA type-A receptors |
US9365502B2 (en) | 2013-03-11 | 2016-06-14 | Washington University | Neuroactive substituted cyclopenta[b]phenanthrenes as modulators for GABA type-A receptors |
US9562026B2 (en) | 2013-03-14 | 2017-02-07 | Washington University | Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors |
WO2014169836A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
WO2014169831A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof |
SI2986623T1 (sl) | 2013-04-17 | 2019-03-29 | Sage Therapeutics, Inc. | 19-NOR C3,3-disubstituirani C21-N-pirazolil steroidi in metode njhove uporabe |
CN112110976B (zh) | 2013-04-17 | 2023-08-29 | 萨奇治疗股份有限公司 | 刺激神经活性的19-去甲类固醇及其使用方法 |
DK3021852T3 (da) | 2013-07-19 | 2021-03-15 | Sage Therapeutics Inc | Neuroaktive steroider, sammensætninger og anvendelser deraf |
WO2015027227A1 (en) | 2013-08-23 | 2015-02-26 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
WO2016061537A1 (en) | 2014-10-16 | 2016-04-21 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
SG10202009859YA (en) | 2014-10-16 | 2020-11-27 | Sage Therapeutics Inc | Compositions and methods for treating cns disorders |
WO2016082789A1 (en) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
EP3250210B1 (en) | 2015-01-26 | 2020-12-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
EP4155314A1 (en) | 2015-02-20 | 2023-03-29 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
EP3481844B1 (en) | 2016-07-11 | 2024-04-17 | Sage Therapeutics, Inc. | C7, c12, and c16 substituted neuroactive steroids and their methods of use |
IL264129B2 (en) | 2016-07-11 | 2024-05-01 | Sage Therapeutics Inc | C20, C17 and C21 converted neuroactive steroids and methods of using them |
CR20210629A (es) | 2019-05-31 | 2022-03-22 | Sage Therapeutics Inc | Esteroides neuroactivos y composiciones de estos |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3043833A (en) * | 1961-07-14 | 1962-07-10 | Ormonoterapia Richter Spa | 17-cyanohydrin of 19-nor androstenedione and 3-derivatives thereof |
DE1183500B (de) | 1962-10-12 | 1964-12-17 | Schering Ag | Verfahren zur Herstellung von alpha, beta-Methylenketonen der Steroidreihe |
US3579509A (en) * | 1965-06-21 | 1971-05-18 | Smith Kline French Lab | Process and 6-beta-substituted ethyl intermediates for preparing 6,6-ethylene-3-keto-delta**4 steroids |
GB1089945A (en) * | 1965-09-23 | 1967-11-08 | British Drug Houses Ltd | Steroidal-6-spirocyclopropyl-4-en-3-ones |
IL32699A (en) * | 1968-07-30 | 1973-06-29 | American Home Prod | 6-substituted-13-polycarbonalkyl-18,19 dinorpregn-4-en-3-ones,their preparation and pharmaceutical compositions containing them |
FR2081561B1 (es) * | 1970-03-03 | 1973-04-06 | Roussel Uclaf | |
US3705179A (en) | 1971-03-15 | 1972-12-05 | American Home Prod | Antiandrogenic steroids |
FR2139708B1 (es) * | 1971-06-01 | 1974-08-23 | Roussel Uclaf | |
US3994937A (en) * | 1972-02-11 | 1976-11-30 | Schering Aktiengesellschaft | 15α,16α-Methylene-4-estren-17β-ols |
BE795241A (fr) | 1972-02-11 | 1973-08-09 | Schering Ag | 15alpha, 16alpha-methylene-4-oestren-17beta-ols-methylenz-4-oestren-17beta-ols et leur procede de preparation |
NL7701384A (nl) | 1977-02-10 | 1978-08-14 | Akzo Nv | Werkwijze voor het bereiden van nieuwe steroiden van de oestraanreeks. |
DE2922500A1 (de) | 1979-05-31 | 1980-12-04 | Schering Ag | 6 beta .7 beta |
US4252800A (en) * | 1979-10-05 | 1981-02-24 | United States Of America | 7α-methylnorethindrone enanthate and its use in long term suppression of fertility in female mammals |
US4544554A (en) * | 1983-09-26 | 1985-10-01 | Ortho Pharmaceutical Corporation | Triphasic oral contraceptive |
DE3402329A1 (de) | 1984-01-20 | 1985-08-01 | Schering AG, 1000 Berlin und 4709 Bergkamen | 6,6-ethylen-15,16-methylen-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate |
DE4344462C2 (de) * | 1993-12-22 | 1996-02-01 | Schering Ag | Zusammensetzung für die Empfängnisverhütung |
EP0785211A1 (en) * | 1996-01-22 | 1997-07-23 | Laboratoire Theramex | New substituted 19-nor-pregnane derivatives |
DE19651000A1 (de) * | 1996-12-01 | 1998-06-04 | Schering Ag | Oxyiminopregnancarbolactone |
DE102004063864A1 (de) | 2004-12-30 | 2006-07-13 | Schering Ag | 18-Methyl-19-nor-17-pregn-4-en21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate |
-
2007
- 2007-06-12 DE DE102007027636A patent/DE102007027636A1/de not_active Withdrawn
-
2008
- 2008-06-04 JP JP2010511525A patent/JP2010529152A/ja active Pending
- 2008-06-04 KR KR1020097025931A patent/KR20100017780A/ko not_active Application Discontinuation
- 2008-06-04 EP EP08758989A patent/EP2178899B1/de not_active Not-in-force
- 2008-06-04 AU AU2008261277A patent/AU2008261277A1/en not_active Abandoned
- 2008-06-04 BR BRPI0813455-3A2A patent/BRPI0813455A2/pt not_active Application Discontinuation
- 2008-06-04 MX MX2009013626A patent/MX2009013626A/es not_active Application Discontinuation
- 2008-06-04 CN CN200880020040A patent/CN101679477A/zh active Pending
- 2008-06-04 WO PCT/EP2008/004428 patent/WO2008151745A1/de active Application Filing
- 2008-06-04 CA CA002689563A patent/CA2689563A1/en not_active Abandoned
- 2008-06-04 ES ES08758989T patent/ES2397879T3/es active Active
- 2008-06-04 RU RU2010100334/04A patent/RU2010100334A/ru not_active Application Discontinuation
- 2008-06-11 TW TW097121799A patent/TW200906846A/zh unknown
- 2008-06-11 PA PA20088784201A patent/PA8784201A1/es unknown
- 2008-06-11 US US12/137,122 patent/US20090048218A1/en not_active Abandoned
- 2008-06-11 PE PE2008000992A patent/PE20090312A1/es not_active Application Discontinuation
- 2008-06-11 UY UY31145A patent/UY31145A1/es not_active Application Discontinuation
- 2008-06-11 CL CL2008001721A patent/CL2008001721A1/es unknown
- 2008-06-12 AR ARP080102498A patent/AR066970A1/es unknown
-
2009
- 2009-11-24 IL IL202300A patent/IL202300A0/en unknown
-
2010
- 2010-01-11 ZA ZA2010/00185A patent/ZA201000185B/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2008151745A1 (de) | 2008-12-18 |
PE20090312A1 (es) | 2009-04-09 |
UY31145A1 (es) | 2009-01-30 |
AU2008261277A1 (en) | 2008-12-18 |
CA2689563A1 (en) | 2008-12-18 |
EP2178899B1 (de) | 2012-10-24 |
CN101679477A (zh) | 2010-03-24 |
IL202300A0 (en) | 2010-06-30 |
BRPI0813455A2 (pt) | 2014-12-23 |
ES2397879T3 (es) | 2013-03-12 |
PA8784201A1 (es) | 2009-01-23 |
RU2010100334A (ru) | 2011-07-20 |
DE102007027636A1 (de) | 2008-12-18 |
CL2008001721A1 (es) | 2008-12-19 |
ZA201000185B (en) | 2011-03-30 |
MX2009013626A (es) | 2010-01-20 |
JP2010529152A (ja) | 2010-08-26 |
US20090048218A1 (en) | 2009-02-19 |
KR20100017780A (ko) | 2010-02-16 |
EP2178899A1 (de) | 2010-04-28 |
TW200906846A (en) | 2009-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR066970A1 (es) | Derivado de 17 beta-ciano-18a-homo-19-nor-androst-4- eno, su uso y medicamento que lo contiene | |
AR066971A1 (es) | Derivado de 17beta-ciano-19-nor-androst-4-eno- su uso y medicamento que lo contiene | |
AR078793A1 (es) | Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros | |
AR060050A1 (es) | Compuestos moduladores del receptor de s1p y uso de los mismos | |
CO6251271A2 (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas | |
AR063240A1 (es) | Derivados de n-aril pirazol,composiciones farmaceuticas que los contienen y usos para el tratamiento de la diabetes tipo2,y enfermedades relacionadas. | |
DOP2006000076A (es) | Derivados de ciclopentapiridina y tetrahidroquinolina | |
AR056025A1 (es) | Compuestos de imidazol sustituidos como inhibidores de ksp | |
AR056204A1 (es) | Derivados de indano como antagonistas de receptores de mch, metodos para su preparacion, intermediarios de sintesis de los mismos, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades relacionadas | |
AR054083A1 (es) | Compuestos imidazol y su utilizacion paar preparar medicamentos | |
PE20210398A1 (es) | Benzofurano, benzopirrol, benzotiofeno sustituidos y otros inhibidores del complemento estructuralmente relacionados | |
ECSP077228A (es) | Proceso para la preparación de derivados de estrona y de estradiol sustituidos en la posición 2 | |
GEP20074256B (en) | Novel benzothiadiazine, process for their preparation and pharmaceutical compositions containing | |
AR046753A1 (es) | Derivados de benzoxazina y usos de los mismos | |
CO5570696A2 (es) | 1-amino-alquilciclohexanos insaturados como antagonistas de los receptores nmda, 5ht3 y nicotinico neuronal | |
AR068381A1 (es) | Compuestos de quinolina apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6 | |
AR052258A1 (es) | Derivados de fenilpiperazinas con una afinidad combinada para receptores de dopamina - d2 y sitios de reabsorcion de serotonina, composiciones farmaceuticas que los contienen y su empleo como medicamentos para el tratamiento de enfermedades del sistema nervioso central. | |
ECSP10010315A (es) | Derivados de 19-nor-esteroide que tiene un grupo 15 ,16 -metileno y un anillo de 17,17-espirolactona saturado, su uso y medicamentos que los comprenden | |
AR069700A1 (es) | Derivados de azetidina,composiciones farmaceuticas que los comprenden, metodo de preparacion, intermediarios de sintesis,y usos de los mismos en el tratamiento o prevencion de trastornos psiquiatricos , del sistema inmune y gastrointestinales, entre otros. | |
UY27544A1 (es) | Derivados de piperazina desestabilizantes del receptor de andrógenos | |
WO2008152112A3 (de) | 17ß-CYANO-19-ANDROST-4-EN-DERIVAT, DESSEN VERWENDUNG UND DAS DERIVAT ENTHALTENDE ARZNEIMITTEL | |
AR057748A1 (es) | Derivados de 2,3 dihidroindol. composiciones farmaceuticas | |
AR069965A1 (es) | Derivado de (gamma)-lactona de esteroide de acido 15, 16 -metilen-17-hidroxi-19-nor-21-carboxilico, su uso para preparar un medicamento que lo contiene y medicamento que contiene al compuesto | |
PE20091181A1 (es) | Derivado 15,16-metilen-17-(1'-propenil)-17-3' -oxidoestra-4-en-3-ona, su uso y medicamento que lo contiene | |
AR074728A1 (es) | Uso de derivados 17-beta-ciano-18a-homo-19-nor-androst-4-eno para preparar un medicamento en forma de deposito para la aplicacion parenteral, asi como medicamentos de deposito que contienen derivados de 17beta-ciano-18a-homo-19-nor-androst-4-eno para la aplicacion parenteral |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |